Drugs / Bivalent Human Papilloma Virus Vaccine
last change Dec 2021 re-read 2 minutes ago

Bivalent Human Papilloma Virus Vaccine

Vaccine

Developed for
common wart
Investigated by
Zagazig University

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05383625 Sep 2020 → Oct 2021 common wart Zagazig University Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bivalent Human Papilloma Virus Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05383625
Modality Vaccine “Bivalent Human Papilloma Virus VaccineNCT05383625